Appointments Archives - Page 43 of 43 - European Biotechnology Magazine

Stay up to date every week with the european biotechnology newsletter.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

Name

This field is for validation purposes and should be left unchanged.

Stay up to date every week with the european biotechnology newsletter.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

This field is for validation purposes and should be left unchanged.

go to the article

go back to the homepage

BIOCOM CARD
Newsletter
Advertising
Job Market
Shop

Latest news
Background
Opinion
The Mag
- Issues
- Special
- Subscribe
Euro Biotech Guide
Market Place
Associations
Service
Events
Search
Menu Menu

Building a diabetes major

Appointments

Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.

3 May 2016

https://european-biotechnology.com/wp-content/uploads/2024/04/ulf-hannelius.jpg 237 210 h.genrich /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png h.genrich2016-05-03 22:19:002016-05-03 22:19:00Building a diabetes major

Page 43 of 43«‹41 4243

LATEST NEWS

Gourmey’s 5,000-liter bioreactor system can achieve a production cost of $3.43 per pound, the lowest in the industry to date with independent validation

Cyril Marcilhacy

UK Food Standards Agency accepts Gourmey’s applic...

Pilot plant to convert syngas into hexanol.

Rheticus/Evonik

First step towards scaling chemical production from...

Nuclidium AG

Nuclidium fuels next radiopharma wave

MAGAZINE

1 / 4

This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … more ➔

2 / 4

This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔

3 / 4

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔

4 / 4

The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … more ➔

❮❯

Building a diabetes major

UK Food Standards Agency accepts Gourmey’s applic...

First step towards scaling chemical production from...

Nuclidium fuels next radiopharma wave

Unlocking the Future of Precision Biology with Spatial Cell Sorting

The Bridge to your success